ID   KDI/20
AC   CVCL_9V30
DR   NCBI_Iran; C637
DR   Wikidata; Q54899708
RX   PubMed=17852455;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 23-02-16; Last updated: 29-06-23; Version: 14
//
RX   PubMed=17852455; DOI=10.1080/10245330701283991;
RA   Nadali F., Pourfathollah A.A., Alimoghaddam K., Nikougoftar M.,
RA   Rostami S., Dizaji A., Azizi E., Zomorodipour A., Ghavamzadeh A.;
RT   "Multidrug resistance inhibition by antisense oligonucleotide against
RT   MDR1/mRNA in P-glycoprotein expressing leukemic cells.";
RL   Hematology 12:393-401(2007).
//